Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from AstraZeneca ( (GB:AZN) ).
AstraZeneca has granted share awards to Chief Executive Officer Pascal Soriot and Chief Financial Officer Aradhana Sarin under its Deferred Bonus Plan and Performance Share Plan, aligning a portion of their 2025 bonuses and long-term incentives with company equity. Soriot received a total of 103,581 ordinary shares and Sarin 42,393 shares at an award price of £152.42, with vesting and holding periods tied to multi-year performance metrics.
The deferred bonus awards will vest after three years, while performance share awards are subject to a three-year performance assessment focused on scientific, commercial, financial, and sustainability outcomes, followed by a two-year holding period. This structure reinforces long-term alignment between executive rewards, the company’s strategic priorities, and shareholder interests, and complies with UK market abuse and disclosure regulations.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £180.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
The score is driven primarily by strong underlying financial performance and a constructive earnings outlook (growth guidance and pipeline progress). This is tempered by valuation (P/E ~30), recent free-cash-flow variability, and technical signals that appear overextended despite the broader uptrend.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca PLC is a global, science-led biopharmaceutical company focused on discovering, developing, and commercialising prescription medicines across Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Headquartered in Cambridge, UK, its medicines are sold in more than 125 countries and used by millions of patients worldwide.
Average Trading Volume: 2,695,814
Technical Sentiment Signal: Buy
Current Market Cap: £229.1B
See more insights into AZN stock on TipRanks’ Stock Analysis page.